Creative Planning
JUNO

Creative Planning’s Juno Therapeutics, Inc. JUNO Stock Holding History

Creative Planning’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-60,649
Closed -$2.77M – 2188
2017
Q4 		$2.77M Sell
60,649
-1,228
-2% -$61.3K 0.01% 378
2017
Q3 		$2.78M Buy
61,877
+11,050
+22% +$377K 0.01% 370
2017
Q2 		$1.52M Buy
50,827
+2,811
+6% +$69.4K 0.01% 524
2017
Q1 		$1.06M Buy
48,016
+34,250
+249% +$735K 0.01% 647
2016
Q4 		$259K Sell
13,766
-28,200
-67% -$690K ﹤0.01% 1269
2016
Q3 		$1.26M Buy
41,966
+12,226
+41% +$380K 0.01% 518
2016
Q2 		$1.14M Buy
29,740
+900
+3% +$37.4K 0.01% 484
2016
Q1 		$1.1M Sell
28,840
-6,555
-19% -$228K 0.01% 469
2015
Q4 		$1.56M Buy
35,395
+4,800
+16% +$238K 0.01% 372
2015
Q3 		$1.25M Buy
+30,595
New +$1.34M 0.01% 420
2015
Q2 		– Sell
-1,240
Closed -$75K – 3670
2015
Q1 		$75K Sell
1,240
-5,976
-83% -$290K ﹤0.01% 1742
2014
Q4 		$377K Buy
+7,216
New +$323K ﹤0.01% 819

Other funds holding JUNO

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Creative Planning's JUNO Position: Q1 2018 in Review

Creative Planning sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 60,649 shares — an estimated $2.77M sold.

Creative Planning first reported a position in JUNO in Q4 2014 and held it in 12 quarters. The position peaked at $2.78M in Q3 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

  • Creative Planning reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Creative Planning sold 60,649 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $2.77M.
  • Creative Planning first reported a position in Juno Therapeutics, Inc. in Q4 2014 and held it in 12 quarters.
  • Creative Planning's Juno Therapeutics, Inc. position peaked at $2.78M in Q3 2017.
  • 2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Creative Planning's 13F filing for Q1 2018, filed 18 Apr 2018.